P1.02-04 the EGFR Resisters Lung Cancer Group: A Patient-Driven Initiative to Understand and Improve Treatments for EGFR+ Lung Cancer

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.674
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Model for Predicting EGFR Mutation Status in Lung Cancer

Breathe
PulmonaryRespiratory Medicine
2019English

P1.02-05 ALK Positive Lung Cancer: Patient Engagement and Partnership

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

EGFR Mutations Status for Non-Small-Cell Lung Cancer Patients

Sveikatos mokslai
2016English

Spatiotemporal T790M Heterogeneity in a Patient With EGFR-Mutant Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2014English

Third Generation EGFR TKI Landscape for Metastatic EGFR Mutant Non-Small Cell Lung Cancer (NSCLC)

Expert Review of Anticancer Therapy
OncologyPharmacology
2019English

Impressive Response to Tyrosine Kinase Inhibitors in a Patient With Respiratory Failure for EGFR -Mutated Metastatic Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2017English

Combined Therapy With EGFR TKI and Gambogic Acid for Overcoming Resistance in EGFR‑T790M Mutant Lung Cancer

Oncology Letters
Cancer ResearchOncology
2015English

Clinical Analysis of EGFR‐ Positive Non‐small Cell Lung Cancer Patients Treated With First‐line Afatinib: A Nagano Lung Cancer Research Group

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2019English

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy